Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
Delayed Nasdaq  -  04:00 2022-11-29 pm EST
204.79 USD   -2.11%
11/23Insider Sell: Alnylam Pharmaceuticals
MT
11/16Transcript : Alnylam Pharmaceuticals, Inc. Presents at Stifel 2022 Healthcare Conference, Nov-16-2022 01:15 PM
CI
11/16Transcript : Alnylam Pharmaceuticals, Inc. Presents at 13th Annual Jefferies London Healthcare Conference 2022, Nov-16-2022 02:05 PM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

Pfizer's $11.6 billion Biohaven buy could spark more biotech deals

05/11/2022 | 01:18pm EST
FILE PHOTO: Biohaven Pharmaceutical Holding Company logo is displayed on screen on floor of NYSE in New York

(Reuters) - Pfizer Inc's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.

The deal, announced on Tuesday, is the biggest in the sector so far this year and ends a dearth of large acquisitions, which along with clinical failures and investor exits following a gradual easing of the pandemic have pummeled biotech stocks.

"One weight on the sector has been a relative lack of M&A of late ... and we think this news may be just what the doctor ordered to restore sentiment," Piper Sandler analyst Christopher Raymond said.

Biotechs are coming off their worst April since 2002, and the crash in valuation has made them attractive M&A targets, especially when small drugmakers are grappling with a cash crunch, analysts say.

Graphic: Biotech index on track to give up most of its pandemic gains - https://fingfx.thomsonreuters.com/gfx/mkt/klvyklwxovg/Biotech%20index%20chart.JPG Wells Fargo analyst Mohit Bansal, who in February named Biohaven as an acquisition target, had also listed Alnylam Pharmaceuticals, Vir Biotechnology and Intellia Therapeutics.

The companies did not immediately respond to Reuters requests for comment.

Pfizer offered a 78.6% premium, or $148.50 per Biohaven share, but that was below the $151.51 price Biohaven shares traded at in October before the months-long selloff in the sector began.

Drugmakers that benefited from their COVID-19 products such as Moderna Inc and BioNTech have also signaled that they have enough cash for deals.

Moderna ended the first quarter with a cash of $19.3 billion, while BioNTech said its cash position was around 10 billion euros ($10.55 billion).

But there has not been "a fundamental shift in seller expectations as of this point," Merck & Co Inc Chief Executive Officer Robert Davis said last month.

"There are some smaller players that do have cash challenges. That's where you could see movement first."

(Reporting by Manas Mishra in Bengaluru; Editing by Ankur Banerjee and Sriraj Kalluvila)

By Manas Mishra


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ALNYLAM PHARMACEUTICALS, INC. -2.11% 204.79 Delayed Quote.23.36%
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. 6.87% 15.4 Delayed Quote.-89.54%
BIONTECH SE 1.31% 163.61 Delayed Quote.-37.36%
INTELLIA THERAPEUTICS, INC. -0.54% 48 Delayed Quote.-59.18%
MODERNA, INC. -1.27% 173.15 Delayed Quote.-30.95%
PFIZER, INC. -0.16% 49.49 Delayed Quote.-16.05%
PIPER SANDLER COMPANIES -0.72% 140.64 Delayed Quote.-20.64%
VIR BIOTECHNOLOGY, INC. 1.15% 27.26 Delayed Quote.-35.63%
WELLS FARGO & COMPANY 1.26% 47.57 Delayed Quote.-2.08%
All news about ALNYLAM PHARMACEUTICALS, INC.
11/23Insider Sell: Alnylam Pharmaceuticals
MT
11/16Transcript : Alnylam Pharmaceuticals, Inc. Presents at Stifel 2022 Healthcare..
CI
11/16Transcript : Alnylam Pharmaceuticals, Inc. Presents at 13th Annual Jefferies ..
CI
11/09Alnylam to Webcast Presentations at Upcoming November Investor Conferences
BU
11/07SVB Securities Adjusts Price Target on Alnylam Pharmaceuticals to $145 From $142, Maint..
MT
11/02HC Wainwright Cuts Price Target for Alnylam Pharmaceuticals to $415 From $430, Maintain..
MT
11/01Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
CI
10/28Morgan Stanley Adjusts Price Target on Alnylam Pharmaceuticals to $210 From $220, Reite..
MT
10/28Goldman Sachs Increases Price Target on Alnylam Pharmaceuticals to $270 From $239, Keep..
MT
10/28Berenberg Bank Adjusts Alnylam Pharmaceuticals' Price Target to $172 From $184, Maintai..
MT
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 1 016 M - -
Net income 2022 -1 132 M - -
Net cash 2022 892 M - -
P/E ratio 2022 -22,9x
Yield 2022 -
Capitalization 25 738 M 25 738 M -
EV / Sales 2022 24,4x
EV / Sales 2023 16,9x
Nbr of Employees 1 665
Free-Float 99,5%
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 209,20 $
Average target price 236,31 $
Spread / Average Target 13,0%
EPS Revisions
Managers and Directors
Yvonne L. Greenstreet Chief Executive Officer & Director
Akshay K. Vaishnaw President
Jeffrey V. Poulton Chief Financial Officer & Executive Vice President
Michael W. Bonney Independent Director
Pushkal P. Garg Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
ALNYLAM PHARMACEUTICALS, INC.23.36%25 738
MODERNA, INC.-30.95%67 378
IQVIA HOLDINGS INC.-23.99%39 832
LONZA GROUP AG-34.32%39 180
SEAGEN INC.-21.59%22 506
CELLTRION, INC.-10.86%17 831